A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone
A phase 3 trial of Daratumumab in multiple myeloma, run by Celltrion, now recruiting.
Overview
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma is a phase 3 interventional study registered as NCT06952478 by Celltrion, with 486 participants planned, started 2025-08-12 and due to reach its primary completion in 2027-11-15. Interventions recorded: CT-P44(Daratumumab), Darzalex Faspro(Daratumumab). Conditions listed: Refractory or Relapsed Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Shares Daratumumab, Multiple myeloma.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Multiple myeloma.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Daratumumab, Multiple myeloma.
- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Daratumumab, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Daratumumab, Multiple myeloma.
- TrialA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas
Shares Daratumumab, Multiple myeloma.
- TrialMajesTEC-3
Shares Daratumumab, Multiple myeloma.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Daratumumab, Multiple myeloma.